Compile Data Set for Download or QSAR
Report error Found 311 of affinity data for UniProtKB/TrEMBL: Q15746
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307609(US10150755, Compound 1 | 2-(6-(4-Cyclopropyl-4H-1,...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307610(US10150755, Compound 3 | US10150755, Compound 2 | ...)
Affinity DataKd: >1.00E+4nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307615(US10150755, Compound 7 | 2-(6-(4-cyclopropyl- 4H-1...)
Affinity DataKd: >1.00E+4nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307636(US10150755, Compound 28 | 2-(6-(4-cyclopropyl- 4H-...)
Affinity DataKd:  6.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307638(US10150755, Compound 30 | 2-(6-(4-cyclopropyl- 4H-...)
Affinity DataKd:  6.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307640(US10150755, Compound 32 | N-(2-(6-(4-cyclopropyl-4...)
Affinity DataKd:  6.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307648(US10150755, Compound 40 | 2-(6-(4-cyclopropyl- 4H-...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307649(US10150755, Compound 41 | 2-(6-(4-cyclopropyl- 4H-...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307654(BDBM307669 | 2-(6-(4-cyclopropyl- 4H-1,2,4-triazol...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307668(US10150755, Compound 60 | 2-(6-(4-cyclopropyl- 4H-...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307671(US10150755, Compound 63 | 2-(6-(4-cyclopropyl-4H-1...)
Affinity DataKd: >1.00E+4nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307672(US10150755, Compound 64 | 2-(6-(4-cyclopropyl-4H-1...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307673(US10150755, Compound 65 | 5-chloro-2-(6-(4-cyclopr...)
Affinity DataKd: >1.00E+4nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307674(US10150755, Compound 66 | 2-(6-(4-cyclopropyl-4H-1...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307676(US10150755, Compound 68 | 2-(6-(4-cyclopropyl-4H-1...)
Affinity DataKd:  6.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307677(US10150755, Compound 69)
Affinity DataKd:  6.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307679(US10150755, Compound 71 | 2-(6-(4-cyclopropyl-4H-1...)
Affinity DataKd:  6.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM307686(US10150755, Compound 78 | 2-(6-(5-methyl-6,7-dihyd...)
Affinity DataKd: <1.00E+3nMAssay Description:MYLK dissociation constants (Kd) for compounds were determined using the DiscoverX KdELECT platform. The MYLK kinase (accession number NP_444254.3) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
Go to US Patent

TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM25118(4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-...)
Affinity DataKd:  3.50E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM6866(1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b ...)
Affinity DataKd:  2.10E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM17055((9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydr...)
Affinity DataKd:  290nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM25045(CHEMBL538346 | mTOR Inhibitor, PI103 | PI-103 | 3-...)
Affinity DataKd:  1.50E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM31094(PKC-412 | cid_24202429)
Affinity DataKd:  2.00E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM31095(5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-yli...)
Affinity DataKd:  360nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM31096(CHEMBL290084 | Staurosporine | cid_451705 | US2024...)
Affinity DataKd:  15nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM4814(SUNITINIB MALATE | CHEMBL535 | N-[2-(diethylamino)...)
Affinity DataKd:  280nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50505542(CHEMBL4576489)
Affinity DataKd:  298nMAssay Description:Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged MYLK (unknown origin) (1428 to 1771 residues) expressed in baculovirus inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50505541(CHEMBL4465866)
Affinity DataKd:  369nMAssay Description:Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged MYLK (unknown origin) (1428 to 1771 residues) expressed in baculovirus inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50652793(CHEMBL5653589)
Affinity DataKd:  0.317nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50652792(CHEMBL3752910)
Affinity DataKd:  206nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/13/2025
Entry Details
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM8344(N-[6-(3-hydroxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3...)
Affinity DataKd:  150nMAssay Description:Binding affinity to human SKMLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
1/11/2010
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM13535(N-(4-isopropoxyphenyl)-4-[6-methoxy-7-(3-piperidin...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50308060(CEP-701 | 16-hydroxy-16-(hydroxymethyl)-15-methyl-...)
Affinity DataKd:  13nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50326053(PKC-412 | CHEMBL608533 | US20240132489, Compound S...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM4814(SUNITINIB MALATE | CHEMBL535 | N-[2-(diethylamino)...)
Affinity DataKd:  23nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM13535(N-(4-isopropoxyphenyl)-4-[6-methoxy-7-(3-piperidin...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM4814(SUNITINIB MALATE | CHEMBL535 | N-[2-(diethylamino)...)
Affinity DataKd:  280nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50326054(CHEMBL1240703)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50326053(PKC-412 | CHEMBL608533 | US20240132489, Compound S...)
Affinity DataKd:  220nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MYLKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50326054(CHEMBL1240703)
Affinity DataKd: >1.00E+4nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataKd:  410nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM50308060(CEP-701 | 16-hydroxy-16-(hydroxymethyl)-15-methyl-...)
Affinity DataKd:  12nMAssay Description:Binding affinity to MLCKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2011
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM15244(cid_3038525 | 5-(2,6-dichlorophenyl)-2-[(2,4-diflu...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding constant for MYLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM4851(cid_151194 | PTK787 | CHEMBL101253 | N-(4-chloroph...)
Affinity DataKd: >1.00E+4nMAssay Description:Binding constant for MYLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM60665(US9145414, R406 | US9212178, R406 | BDBM50249542 |...)
Affinity DataKd:  6.50E+3nMAssay Description:Binding constant for MYLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM17055((9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydr...)
Affinity DataKd:  290nMAssay Description:Binding constant for MYLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetMyosin light chain kinase, smooth muscle(Human)
Seal Rock Therapeutics

US Patent
LigandPNGBDBM31095(5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-yli...)
Affinity DataKd:  360nMAssay Description:Binding constant for MYLK kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
Displayed 1 to 50 (of 311 total ) | Next | Last >>
Jump to: